TSLP inhibitors and receptor antagonists present significant market opportunities for treating various inflammatory diseases due to their ability to modulate key inflammatory pathways. Expanding ...
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR ( m ammalian T arget O f R apamycin) inhibitor. mTOR has been shown to have a significant ...
INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Massive ovarian oedema (MOE) is a rare benign condition that can mimic ovarian neoplasms and lead to unnecessary oophorectomy ...
Interstitial lung disease (ILD) represents one of the most severe and clinically impactful manifestations of systemic autoimmune diseases, contributing ...
Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in ...
KOMZIFTI (ziftomenib) net product revenue in first full quarter of commercialization - - Robust new patient starts and early launch dynamics, including repeat use, switching and combination ...
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations from the company’s ...
Scientists at UCSF have discovered a new human cell, DSC4, found only in the initial weeks of pregnancy. This cell might ...
FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company ...
Tumors do not communicate only with immune cells, blood vessels, and stromal tissue. A growing body of evidence suggests that cancer can also co-opt the nervous system, reshaping the tumor ...
Microfluidic architecture with vascular and tumor chambers recreates perfusion and desmoplastic stroma, enabling longitudinal visualization of PDAC cell–stromal dynamics under near-physiologic flow.